VectorY lands €30M EIB loan to push its ALS therapy
What's the deal? The European Investment Bank (EIB) has signed a €30 million convertible loan with Amsterdam-based VectorY Therapeutics, a clinical-stage biotech developing treatments for neurodegenerative diseases including ALS and Huntington's disease. The financing is part of a broader syndicate of new investors and existing shareholders.
What's the endgame? VectorY's platform uses a "targeted delivery vehicle" that carries genetic instructions into cells of the central nervous system, prompting them to produce disease-fighting antibodies themselves. The approach is designed to deliver long-term treatment from a single administration, overcoming the repeated injections conventional antibody therapies require.
Why now? The money follows a concrete clinical milestone. VectorY's lead ALS candidate, VTx-002, entered a Phase 1/2 trial, with the first participant dosed in February 2026; the study has since expanded.
Where it fits: The loan ranks in the top 3% of all-time convertible rounds for Dutch health companies, by amount. It builds on VectorY's €129 million Series A in 2023, one of Europe's larger biotech financings that year.
The EIB investment is backed by the European CommissionDealroom has a profile for this one. Try Dealroom →'s InvestEU programme. "Neurodegenerative diseases are devasting and often fatal, with few effective treatments," said Chantal Schrijver, head of the EIB Group's Amsterdam office.
What could go wrong? The trial is early-stage and primarily designed to assess safety, not whether the treatment works. VTx-002 targets TDP-43 pathology, a promising but still unproven avenue for ALS.
The signal: The round reflects European institutions translating substantial backing into human testing, rather than evidence of a breakthrough — and Brussels' push to build what Commission representative Cecilia Thorfinn called a "more innovative, resilient and competitive Europe" in biotech.
Read more: eib.org
Image credit: Generated with Gemini
